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Nuclear receptors and their coregulators in kidney. Nuclear re-
ceptors are transcription factors that are essential in embryonic
development, maintenance of differentiated cellular pheno-
types, metabolism, and apoptosis. Dysfunction of nuclear
receptor signaling leads to a wide spectra of proliferative, re-
productive, and metabolic diseases, including cancers, infertil-
ity, obesity, and diabetes. In addition, many proteins have been
identified as coregulators which can be recruited by DNA-
binding nuclear receptors to affect transcriptional regulation.
The cellular level of coregulators is crucial for nuclear receptor-
mediated transcription and many coregulators have been shown
to be targets for diverse intracellular signaling pathways and
posttranslational modifications. This review provides a general
overview of the roles and mechanism of action of nuclear recep-
tors and their coregulators. Since progression of renal diseases
is almost always associated with inflammatory processes and/or
involve metabolic disorders of lipid and glucose, cell prolifera-
tion, hypertrophy, apoptosis, and hypertension, the importance
of nuclear receptors and their coregulators in these contexts will
be addressed.
Nuclear receptors comprise a family of transcrip-
tion factors that regulate gene expression in a ligand-
dependent manner. The nuclear receptor superfamily
presently includes 49 distinct members for steroid hor-
mones, such as estrogens and glucocorticoids, recep-
tors for nonsteroidal ligands, such as thyroid hormones
and retinoic acid, as well as receptors that bind diverse
products of lipid metabolism, such as fatty acids and
prostaglandins [1]. The nuclear receptor superfamily also
includes a large number of orphan receptors for which
regulatory ligands have not been identified [2]. Nuclear
receptors exert diverse roles in the regulation of growth,
development, and homeostasis. Members of the nuclear
receptor superfamily directly activate or repress target
genes by binding to hormone response elements (HREs)
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in promoter or enhancer regions which provide speci-
ficity to receptor homodimer/heterodimer binding, and
by binding to other DNA sequence-specific activators.
They also inhibit the transcriptional activities of other
classes of transcription factors by transrepression [3].
Recent studies have also led to the identification of
many associated proteins that interact with nuclear re-
ceptors in a ligand-dependent manner to mediate their
transcriptional regulation. These factors with no spe-
cific DNA-binding affinity have been called nuclear re-
ceptor coregulators. Regulation of gene transcription by
nuclear receptors requires the recruitment of coregula-
tors, with ligand-dependent exchange of corepressors for
coactivators serving as the basic mechanism for switch-
ing from gene repression to activation. In this review, we
will discuss nuclear receptors, with particular emphasis
on the roles of the coactivator/corepressor in gene tran-
scriptional regulation, and its significance role in control-
ling inflammatory processes and metabolic disorders in
kidney.
NUCLEAR RECEPTORS
Basic structure of nuclear receptors
The nuclear receptor superfamily consists of 49 nuclear
receptors (Table 1). The structure for all members is very
similar. It usually contains four major functional domains
(Fig. 1): the N-terminal ligand-independent transactiva-
tion domain (A/B domain), the DNA binding domain
(DBD or C domain), hinge region (D domain) and the C-
terminal E/F domain, including ligand-binding domain,
and the ligand-dependent transactivation domain. The N-
terminal A/B domain contains a transactivation domain
(AF-1) which is of variable length and sequence in the dif-
ferent family members and is recognized by coactivators
and/or other transcription factors. The ligand-binding do-
main is connected to the DBD domain by a short flexi-
ble linker and mediates ligand-dependent transactivation
functions. A short conserved helical sequence within the
carboxyl terminus of the ligand-binding domain, referred
to as activation function 2 (AF-2), is required for ligand-
dependent activation [4, 5].
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Table 1. Nuclear receptor family
Name Abbreviation Ligand
Thyroid hormone receptora,c TRa Thyroid hormone
TRb Thyroid hormone
Retinoic acid receptora RARa Retinoic acid
RARb Retinoic acid
RARc Retinoic acid
Peroxisome proliferators activated receptora PPARa Fatty acid, leukotriene B4, fibrate
PPARb Fatty acids
PPARc Fatty acids, prostaglandin J2
Reverse erbAb,c Rev-erb a Orphan
Rev-erb b Orphan
RAR-related orphan receptorb,c ROR a Cholesterol, cholesteryl sulphate
RORb Retinoic acid
RORc Retinoic acid
Liver X receptora LXRa Oxysterols, T0901317, GW3965
LXRb Oxysterols, T0901317, GW3965
Farnesoid X receptora FXRa Bile acids, fexaramine
FXRb Lanosterol
Vitamin D receptora,b VDR 1,25 (OH)2vitamin D3, litocholic acid
Pregnane X receptor PXR Xenobiotics, PCN
Constitutive androstane receptor CAR Xenobiotics, phenobarbital
Human nuclear receptor 4b HNF4a Orphan
HNFc Orphan
Retinoid X receptor RXRa Retinoic acid
RXRb Retinoic acid
RXRc Retinoic acid
Testis receptor TR2 Orphan
TR4 Orphan
Tailless TLL Orphan
Photoreceptor-specific receptor PNR Orphan
Chicken ovalbumin upstream-promoter transcription factorb COUP-TFI Orphan
COUP-TFII Orphan
ErbA2-related gene-2 EAR2 Orphan
Estrogen receptorb ERa Estradiol-17b , tamoxifen, raloxifene
ERb Estradiol-17b ,various synthetic compounds
Estrogen receptor-related receptor ERRa Orphan
ERRb DES, 4-OH tamoxifen
ERRc DES, 4-OH tamoxifen
Glucocorticoid receptorb GR Cortisol, dexamethasone
Mineralocorticoid receptorb MR Aldosterone, spirolactone
Progesterone receptorb PR Progesterone, medroxyprogesterone acetate,
RU468
Androgen receptorb AR Testosterone, flutamide
NGF-induced factor Bc NGFIB Orphan
Nur related factor 1 NURR1 Orphan
Neuron-derived orphan receptor1 NOR1 Orphan
Steroidogenic factor 1c SF1 Orphan
Liver receptor homologous- protein 1 LRH1 Orphan
Germ cell nuclear factor GCNF Orphan
DSS-AHC critical region on the chromosome, gene1 DAX1 Orphan
Short heterodimeric partner SHP Orphan
aHeterodimers with retinoid X receptor; bHomodimers; cMonomers RXR.
Function of nuclear receptors
The nuclear receptors are essential in embryonic de-
velopment, maintenance of differentiated cellular phe-
notypes, and metabolism. The activity of many nuclear
receptors is controlled by the binding of small, lipophilic
ligands that include hormones, metabolites such as fatty
acids, bile acids, oxysterols, and xeno- and endobiotics.
Many nuclear receptors control glucose, cholesterol, bile
acid, and xenobiotic metabolism. The major function of
these nuclear receptors is to act as sensors of the above
molecules to bring about molecular control of impor-
tant metabolic pathways. Once activated by a ligand,
they control a variety of genes for several pathways
of intermediary metabolism. In general, nuclear
receptors have four functions, including ligand-
dependent transactivation, ligand-dependent coactiva-
tion, active repression, and transrepression as shown in
Figure 2.
Ligand-dependent transactivation and coactivation.
The typical activity of nuclear receptors is ligand-
dependent transactivation (Fig. 2A). In the presence of
ligands, nuclear receptors can activate target genes by
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Fig. 1. Domains of nuclear receptors and co-activator proteins. (A) Nuclear receptor structure. Nuclear receptor contains four major functional
domains: the N-terminal ligand-independent transactivation domain (A/B domain), the DNA binding domain (DBD or C domain), hinge region
(D domain), and the C-terminal E/F domain, including ligand-binding domain (LBD) and the ligand-dependent transactivation domain. (B) The
p160 coactivator structure, including the amino terminus (PAS and bHLH homology regions), a central region that interact with nuclear receptors
[such as retinoic acid receptor (RAR), estrogen receptor (ER) and thyroid hormone receptor (TR)] and involved in nuclear receptor interaction
and transaction, and a carboxy-terminal region mediate interactions with either CBP/p300 or protein-arginine methyltransferase CARM1. (C)
CBP/p300 structure. Regions involved in interaction with STAT1 and STAT2, nuclear receptors [retinoic acid receptor (RAR), estrogen receptor
(ER), and retinoid X receptor (RXR)], Jun, CREB, YY1, Fos, E1A, p/CAF, pp90RSK, and SRC-1 are indicated. (D) The structure for nuclear
receptor corepressor (NCoR). Regions involved in interaction with Siah2, Sin3A, Sin3B and nuclear receptors are indicated. Abbreviations are:
bromo, bromodomain; bHLH, basic helix-loop-helix; PAS, period/ary hydrocarbon receptor/single minded; S/T-rich, serine/threonine-rich domain;
CH, cysteine-rich; rich-Q, glutamine-rich domain; TBP, TATA-binding protein; RD, repression domain; AB, acidic basic; H, a helical.
binding directly to HREs as monomers [e.g., steroido-
genic factor 1 (SF1)]; homo- (e.g., steroid receptor) or het-
erodimers with the promiscuous retinoid X receptor [e.g.,
retinoic acid receptor, peroxisome proliferator activated
receptor c (PPARc), thyroid hormone receptor, vitamin
D receptor, and several orphan nuclear receptors]. There
is an allosteric interaction between heterodimeric nuclear
receptors [6]. Some heterodimeric combinations, such
PPAR-retinoid X receptor, can be activated in response
to either PPAR ligands or 9-cis RA which is a retinoid X
receptor ligand. In contrast, other heterodimeric combi-
nations, including retinoid X receptor-retinoic acid recep-
tor, and retinoid X receptor-thyroid hormone receptor
heterodimers, exhibit transcriptional responses that are
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Fig. 2. Transcriptional activities of nuclear
receptors. Members of the nuclear recep-
tor family can both activate and inhibit
gene expression. (A) Transactivation: the
prototypic activity of nuclear receptors is
ligand-dependent activation of transcription
upon binding to specific hormone-response
elements (HREs) in target genes. (B) Coacti-
vation. Nuclear receptors have also been doc-
umented to contribute to gene activation by
acting as coactivators for other transcription
factors (TF), as demonstrated in the case of
the glucocorticoid receptor for certain STAT-
5-responsive genes. (C) Active repression. A
subset of nuclear receptors that heterodimer-
ize with the retinoid X receptor, including the
thyroid hormone receptor, and retinoic acid
receptor, are capable of actively repressing
target genes upon binding to HREs in the ab-
sence of ligand. (D) Transrepression. In ad-
dition, several nuclear receptors, exemplified
by the glucocorticoid receptors are capable of
suppressing target genes by inhibiting the ac-
tivities of other classes of transcription factors,
such as AP-1, in a ligand-dependent manner.
This effect does not require DNA binding by
the nuclear receptor.
selective for retinoic acid and thyroid hormone recep-
tor ligands, respectively. Selective responses have been
demonstrated to result from allosteric interactions be-
tween retinoic acid receptor or thyroid hormone recep-
tor and retinoid X receptor that prevent the binding of
retinoid X receptor ligands. Thus, the transcriptional re-
sponse of the retinoic acid receptor-retinoid X receptor
heterodimer remains retinoic acid receptor–specific, but
retinoid X receptor ligands can serve to potentiate this
response [7].
Ligand-dependent transactivation by nuclear recep-
tors has been found to depend on a highly conserved
motif in ligand-binding domains, referred to as AF-2 [5].
In the unliganded retinoid X receptor structure, the AF-2
helix extends away from the ligand-binding domain [8],
whereas in the agonist-bound retinoic acid receptor c,
thyroid hormone receptor a, estrogen receptor, and
PPARc ligand-binding domain structures, the AF-2 helix
is tightly packed against the body of the ligand-binding
domain and makes direct contacts with ligand [9]. These
studies have suggested that ligand-dependent changes in
the conformation of the AF-2 helix result in the forma-
tion of a surface (or surfaces) that facilitates activation of
target genes.
In addition, nuclear receptors can activate target genes
by acting as coactivators and binding other classes of
DNA-bound transcription factors, as demonstrated in
the case of the glucocorticoid receptor for certain signal
transducer and activator of transcription (STAT)-5 re-
sponsive genes. This effect does not require DNA binding
and is termed ligand-dependent coactivation (Fig. 2B).
Active repression and transrepression. Certain nuclear
receptors, such as glucocorticoid receptor, needs to be
complexed with ligand to translocate to the nucleus and
bind DNA. Other receptors are capable of binding to
DNA in the unliganded state and are associated with
repressor complexes that actively repress transcription.
For example, unliganded liver X receptor inhibits its tar-
get gene adenosine triphosphate (ATP)-binding cassette
transporter A1 (ABCA1) expression [10]. Other subsets
of nuclear receptors that heterodimerize with the retinoid
X receptor, including the thyroid hormone receptor and
retinoic acid receptor, are also capable of actively repress-
ing target genes upon binding to HREs in the absence of
ligand. This repression has been called as active repres-
sion of nuclear receptor (Fig. 2C).
Ligand-dependent activation of nuclear receptors
could alter the expression of a component of a sig-
nal transduction pathway that exerts a negative ef-
fect, termed ligand-dependent transrepression (Fig. 2D).
For example, glucocorticoid receptor has also been
demonstrated to inhibit nuclear factor-kappaB (NF-jB)
function in lymphocytes, in part, by up-regulating the ex-
pression of the inhibitory factor IjBb [11]. Activation
of the glucocorticoid receptor also blunts the response
of an activating protein-1 (AP-1)–dependent promoter
to phorbol ester or Ras stimulation [12]. Similar results
have also been found in other nuclear receptors, such as
retinoic acid receptor [13].
Multiplicity of nuclear receptors
Some nuclear receptors have many paralogues for a
given ligands (Table 1). For example, three paralogues
exist for retinoic acid receptor, PPAR, retinoid X re-
ceptor, retinoic acid receptor–related orphan receptor
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(ROR), and two paralogues for thyroid hormone recep-
tor, estrogen receptor, liver X receptor, and, farnesoid
X receptor. The multiplicity of nuclear receptors is im-
portant for both signal diversification and specification.
For example, estrogen signaling depends on a balancing
act between estrogen receptor a and estrogen receptor b .
Estrogen receptor a is often an activating factor, whereas
estrogen receptor b suppresses the effects of estrogen re-
ceptor a though the ligands are the same [14]; glucocor-
ticoid receptor a mediates the anti-inflammation effect
of corticosteroids, but glucocorticoid receptor b acts as a
dominant-negative form of glucocorticoid receptor [15].
Three PPAR, retinoic acid receptor isoforms also have
distinct functions. The multiplicity of nuclear receptors
also appears to have the facility that one isoform controls
multigenes with opposite biologic effects. For example,
liver X receptor activates both ABCA1 gene and sterol-
responsive element-binding protein 1c (SREBP1c) gene
expression. Induction of ABCA1 gene increases choles-
terol efflux from peripheral tissue and reduces atheroscle-
rosis, whereas activation of SREBP1c seems to increase
fatty acids synthesis and plasma very low-density lipopro-
tein (VLDL) level [10]. The net effect depends on a fine
balance between various factors relating the ratio of nu-
clear receptor isoforms, the specificity of the ligands, and
recruitment of coregulators.
NUCLEAR RECEPTOR COREGULATORS IN
TRANSCRIPTIONAL REGULATION
In the past several years, a large number of nuclear re-
ceptor coregulators have been identified (Table 2). These
proteins, including coactivators and corepressors, are as-
sociated with nuclear receptors in a ligand-dependent
manner. In general, ligand binding is believed to increase
the affinity of nuclear receptors for coactivators [16].
Ligand-dependent recruitment of coregulators is depen-
dent on a ligand-dependent conformational change in
AF-2. On the other hand, an important aspect of antag-
onist action is to place the AF-2 helix in a configuration
that prevents coactivator binding.
Nuclear receptor coactivators (NCoA)
A large number of potential NCoAs have been identi-
fied [6]. Although coactivator proteins show little or no
DNA-binding ability of their own, they are capable of
increasing or inducing transcriptional activity.
The p160 family. The P160 family has been identified
as major proteins interacting with nuclear receptors. The
family contains three homologues, termed (1) NCoA1/
steroid receptor coactivator 1 (SRC1)/p160 (/is “also
known as” or “alias”) (Table 2), (2) NCoA2/trans-
criptional intermediary factor 2 (TIF2)/glucocorticoid
receptor interacting protein 1 (GRIP1)/p160, and
(3) NCoA3/p300 cyclic adenosine monophosphate
(cAMP) response element binding protein (CREB)-
binding protein (CBP)-cointegrator-associated pro-
tein (pCIP)/receptor-associated co-activator 3 (RAC3)/
amplified in breast cancer 1 (AIB1)/activator of the
thyroid and receptor activator (RA) (ACTR)/thyroid
hormone receptor-activator molecule 1 (TRAM1)/p160
[6]. The p160 factors consisting of above three mem-
bers exhibit a common domain structure (Fig. 1B).
These proteins are most highly related in an amino-
terminal region that contains a period/aryl hydrocarbon
receptor/single minded (PAS)-A-basic helix-loop-helix
(bHLH) homology domain. PAS domains have been
shown to function as dimerization motifs. The central con-
served domain mediates ligand-dependent interactions
with nuclear receptor, ligand-binding domain, whereas
the conserved C-terminal transcriptional activation do-
mains mediate interactions with either CBP/p300 or
protein-arginine methyltransferase, such as coactivator-
associated arginine methyltransferase (CARM1) and
protein arginine methyltransferase (PRMT1) [18, 19].
Analysis of the amino acid sequences of the nuclear re-
ceptor interaction domains (central domains) of p160
factors revealed the presence of leucine-rich motifs of
the consensus sequence LXXLL, where L represents
leucine and X any amino acid. The LXXLL sequence
and a short stretch of amino- and carboxy-terminal
amino acids are both necessary and sufficient for ligand-
dependent interactions of p160 proteins with nuclear re-
ceptor ligand-binding domains [20]. Different LXXLL
motifs are selectively required to support functions of
different nuclear receptors. This functional specificity
correlates with the difference in affinity between each
LXXLL motif and different nuclear receptors. Mice lack-
ing p160 factors, such as NCoA1/SRC1/p160 are viable
and grossly normal, probably because of functional re-
dundancy between the three class members. Neverthe-
less, deletion of NCoA1/SRC1/p160 results in steroid
and thyroid hormone resistance [21]. Increased level
of NCoA3/pCIP/RAC3/AIB1/ACTR/TRAM1/p160 has
been found in breast cancers [22].
CBP/p300. CBP was originally isolated on the ba-
sis of its association with CREB in response to cyclic
adenosine monophosphate (cAMP) signaling. Its close
homologue, p300, was purified as a cellular binding pro-
tein of the adenoviral protein E1A. CBP and p300
have been identified as crucial components of nuclear
receptor transactivation and have been shown to di-
rectly interact with numerous members of the nuclear
receptor coregulators. For example, it has been shown
that NCoA1/SRC1/p160 interacts with CBP through two
helical domains that contain the core LXXLL consen-
sus sequence [20]. NCoA6/activating signal cointegra-
tor 2 (ASC2)/nuclear receptor-activating protein 250
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Table 2. Nuclear receptor coregulators
Chromatin remodeling and acetylation Proliferation/apoptosis Bromodomain proteins
ADA2 ARA24/RAN/TC4 p120/SMAP
ADA3 Bcl3 HMG proteins
BRG1 BRCA1 HMG1
CBP Cyclin D1 TRIP7/HMG17-like
GCN5 E1A BZIP factors
MTA1 Nm23-1 p45/NF-E2
NcoA62 Nm23-2 Cytoskeleton
P300 p53 TRIP5/EG5
PCAF Rbp2 TRIP11/TRIP230/CEV14
Prothymosina REA/BAP37/D-prohibition Miscellaneous
RbAp48 RAP46/BAG-1 CRABPII
RIP140 TRIP10/CIP4 NIX
SSN6 TRIP13/HPV16 NRIF3/b3-endonexin
TIF1 Zac1/Lot1 PELP1/p160
Methyltransferases RNA/RNA interacting proteins PNRC2
CARM CIA/KIAA1637 RBF1/ATP synthgase
PIMT dUTPase SUN-CoR/C1D
PRMT1 L7/SPA/L7a/TRUP TRIP3/CG8204
NcoAs MINT/SHARP/KIAA0929 TRIP4/ASC1
NcoA1/SRC1/p160 p72/p68 Not in GeneBank
NcoA2/TIF2/GRIP1/SRC2/p160 PGC1 ARA267a
NcoA3/pCIP/ACTR/AIB1/RAC3/TRAM1/SRC3/p160 PSF/NonO/p54nrb ERAP160/p160
SRA p3/BCATm
NcoA4/ARA70 TLS/p65 p48
NcoA6/ASC2/RAP250/NCR/PRIP/TRBP/AIB3 Cytokine-associated proteins p80
NF-jB/p65 p140
NCoRs p50/Rel PNRC
NcoR1/RIP13 PIASxa/ARIP3 TRAC
NcoR2/SMRT/TRAC1 PIASxb/MIZ1 VIP(170)
Mediator-related proteins PIAS1/GBP LIM domain proteins
TRAPs (complex) PIAS3 ARA55/Hic5
TRAP80/DRIP80/CRSP77 TRIP9/IjBb FHL2/DRAL/Slim3
TRAP95/DRIP92 TRIP14/p59 TRIP6/OIP1/ZRP1
TRAP100 SIN-associated proteins Basal transcription factors
TRAP150 mSin3a CAK
TRAP170/CRSP150/CXORF4 mSin3b dTAFii110
TRAP230 SAP18 MBF1
TRAP240 SAP30 MMS19
PBP/TRIP2/TRAP220/DRIP205/RB18A EF-hand proteins TAF(ii)30
DRIPs (complex) REC55/E6BP/RCN2/VAF1 TBP
PC2 Forkhead proteins TFIIB
PC4 FKHR TFIIF
Proteolysis Zinc finger proteins TFIIH
JAB1 FOG2 TMF/ARA160
TRIP1/Sug1 RIP110/RAP80 SMADs
TRIP12/E6-AP TRIP8/Hairless/5qNCA Smad3
TRIP15/Alien/COP9-S2 POU-domain proteins Smad7
Ubc9 Oct1 RING proteins
ARA54/RNF14/HFB30
SNURF/RNF4
/means “also known as.”
(RAP250)/nuclear receptor coregulator (NRC)/PPAR-
interacting protein (PRIP)/thyroid hormone receptor-
binding protein (TRBP)/AIB3 has been recently charac-
terized to interact not only with nuclear receptors via an
LXXLL motif in the N-terminal, but also with CBP/p300
in its C-terminus [23]. This interaction is in a ligand-
dependent manner and relies on the conserved nuclear
receptor functional domain AF-2. CBP can also asso-
ciate with the CBP-associated factor (p/CAF) [24] and
with RNA polymerase II holoenzyme [25]. Thus, CBP
recruits a series of coactivators and other components
of the transcriptional apparatus to form a large complex
which appears to function in nuclear receptor–dependent
gene expression (Fig. 1C). Deletion of CBP or p300 in
mice results in early death in embryogenesis, suggesting
precise levels of p300/CBP are important in development
and transcription control [26–28].
Other coactivators. In addition to the p160 family and
CBP/p300, a large number of coactivators have been
identified using biochemical and expression cloning
studies. These include NCoA4/androgen receptor activa-
tor 70 (ARA70), PPAR binding protein (PBP)/thyroid
hormone receptor interacting protein 2 (TRIP2)/thyroid
hormone receptor-associated protein 220 (TRAP220)/
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vitamin D receptor interacting protein 205 (DRIP205)/
reinoblastomas suppressor protein 18A (RB18A),
DRIP130/coactivator required for Sp1 activation
130 (CRSP130),TR associated protein (TRAP80, 93,
95,97,100,150,170,220, and 230), p140 factors [estrogen
receptor-associated protein 140 (ERAP140) and RIP140,
GRIP95, 120, 170, TRIP1, and TIF1 (Table 2)]. However
the functions for these proteins are less informative.
Tissue and pathway speciﬁcity of coactivators. Many
coregulators normally show tissue-specific distribution,
and the levels of different coactivators, for example CBP,
can vary dramatically among specific cell types [29]. Such
differences in expression levels might indicate cell speci-
ficity of nuclear receptor–mediated transcriptional reg-
ulation, and might partially explain how the same gene
can be regulated differentially in different cell types [30].
For example, PPARc can activate transcription of the un-
coupling protein 1 (UCP-1) gene in brown fat but not
in fibroblasts [31]. The levels of cold-inducible coacti-
vator PPARc coactivator 1 (PGC1) are normally low
in brown fat cells but can be dramatically increased by
thermal stimulation and subsequently provide a cell-
and tissue-specific mechanism for transcriptional regu-
lation by PPARc in brown fat [31]. p/CIP/SRC3 exerts
effects on somatic growth, modulating cell-autonomous
cell cycle events [32, 33]. Cell-specific coactivators may
also play critical roles in gene-specific transcriptional
activation. Comparing the p160 family and CBP/p300,
some coactivators seem to be more tissue specific. For
example, ARA70, which is expressed in prostate, has
been identified an androgen receptor specific coactiva-
tor. GRIP95,120, and 170 and TRAP80 are also specific
coactivators for glucocorticoid receptors and thyroid hor-
mone receptors.
Different classes of signal-activated transcription fac-
tors require distinct coactivator components, including
CBP, the p160 family members, and p/CAF. For exam-
ple, the steroid-activated nuclear receptors require CBP,
NCoA1/SRC1, p/CIP, and p/CAF [6], whereas cAMP-
activated CREB requires CBP, p/CIP, and p/CAF but not
NCoA1/SRC1 [34]. Interferon gamma (INF-c)-activated
STAT-1 requires the action of CBP and pCIP but neither
p/CAF nor NCoA1/SRC1 [28]. These data suggest that
nuclear receptors and their coactivators could be a key
to determine tissue-specific transactivation.
Corepressors: Nuclear receptor corepressor (NCoR) and
silencing mediator for retinoic acid and thyroid hormone
receptors (SMRT)
Unliganded nuclear receptors that have the ability to
bind DNA and steroid receptors on treatment with an-
tagonists recruit corepressor proteins that inhibit tran-
scription [35, 36]. A factor of ∼270 kD that mediates
repression effects by unliganded thyroid hormone recep-
tors and retinoic acid receptors has been identified. This
protein is termed NCoR [37, 38], a portion of which had
been isolated previously in a yeast two-hybrid screen as
RIP13 [39]. The highly related factor SMRT has also been
identified [40].
NCoR and SMRT appear to be the major proteins as-
sociated with transcription repression for a number of
nuclear receptors in the unliganded state (called active
repression Fig. 2C). Deletion of the murine NCoR locus
relieves nuclear receptor–mediated repression of specific
genes [41]. The binding of either NCoR or SMRT to unli-
ganded nuclear receptors, such as thyroid hormone recep-
tors and retinoic acid receptors, is robust and is enhanced
either by addition of receptor antagonists or the deletion
of the AF-2 domain [37, 40]. Furthermore, unliganded
steroid hormone receptors, such as glucocorticoid recep-
tors and estrogen receptors, do not appear to interact with
NCoR or SMRT, but strong interactions are observed in
the presence of antagonists [42, 43]. The recruitment of
NCoR or SMRT appears to be essential for the antagonist
activity of nuclear receptors.
Both NCoR and SMRT contain a conserved bipartite
nuclear receptor interaction domain (Fig. 1D) [44, 45]
and interact with unliganded nuclear receptors in a fash-
ion analogous to that utilized by coactivators with lig-
anded receptors. Interaction of NCoR and SMRT with
unliganded nuclerar receptors is mediated by a conserved
extended helical motif, referred to as the CoRNR box,
of consensus sequence LXXI/HIXXXI/L which utilizes
overlapping surfaces with LXXLL motif in co-activators
for interactions with nuclear receptors [46].
COACTIVATOR AND COREPRESSOR
COMPLEXES
Both coactivators and corepressors recruit multifac-
tors to form complexes. Binding of ligand results in a
conformational change in the ligand-binding domain that
reduces affinity for NCoR and SMRT complexes while si-
multaneously enhancing affinity for coactivators that con-
tain a conserved LXXLL interaction motif [47], thereby
converting the receptor from a transcriptional repressor
to an activator (Fig. 3). This exchange could be a molec-
ular switch for gene activation.
Coactivator complexes
As chromatinized transcription units are “repressed”
compared with naked DNA, a critical aspect of gene
activation involves nucleosomal remodeling [48]. It is
believed that nuclear receptor–mediated transcription
requires several different protein complexes that can
act sequentially, combinatorially, or in parallel. One pri-
mary step is believed to be the recruitment of proteins
that disrupt chromatin formation. Two general classes of
chromatin remodeling factors have been identified that
appear to play critical roles in transcriptional activation
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Coactivator
SWI•SNF•BRG CBP/p300
p/CAF
TRAP•DRIP•ARC
TAF
TATA Pol
II
TBP
NcoR•mSin3•HDAC1,2SMRT•HDAC3•TBLClass IIHDACs 4,5,7
Corepressor
Repression
Activation
Fig. 3. “Yin-Yang” balance between coactivator and corepressor complexes in regulation of gene transcription. Different protein complexes can act
either sequentially, combinatorially, or in parallel, to manipulate gene transcription. The SWI-SNF complex and the CBP·p/CAF possess adenosine
triphosphate (ATP)-dependent chromatin remodeling and histone acetyltransferase activities, respectively. These complexes may act in concert to
relieve chromatin-mediated repression, with the TRAP·DRIP·ARC complex functioning to recruit core transcription factors RNA polymerase II.
Corepressor complexes include the NCoR·SIN3·HDAC, SMRT·HDAC3·TBL1 and HDACs 4.5,7 which possess histone deacetylase activity and
functions are augmented by additional interactions. HDACs are thought to reverse the actions of histone acetyltransferase-containing complexes.
Binding of hormone or ligand results in a conformational change in ligand-binding domain that reduces affinity for NCoR and SMRT complexes,
while simultaneously enhancing affinity for coactivators complexes.
by nuclear receptors. These are ATP-dependent nucle-
osome remodeling complexes and factors that contain
histone acetyltransferase (HAT) activity.
Switch (SWI)·Sucrose nonfermenting (SNF): ATP-
dependent chromatin remodeling complexes. The yeast
SWI-SNF complex facilitates the binding of sequence-
specific transcription factors to nucleosomal DNA and
can cause local changes in chromatin structure in an ATP-
dependent manner [49]. SWI2/SNF2 protein is contained
in a native multisubunit complex of ∼2 MDa termed
SWI/SNF and has sequence motifs closely related to those
found in DNA-stimulated ATPases/DNA helicases [50].
Mammalian homologues of Drosophila SWI2/SNF2 such
as Brg1 and Brm function as components of large mul-
tiprotein complexes that contain components related to
subunits of yeast SWI/SNF [51, 52]. Both Brg1 and Brm
have been shown to interact with the nuclear receptor in
a ligand-dependent fashion [53]. Transfection of ATPase-
defective alleles of either Brg1 or Brm into several mam-
malian cell lines leads to a significant decrease in the abil-
ity of several nuclear receptors to activate transcription,
including retinoic acid receptors, estrogen receptos, and
glucocorticoid receptors to activate transcription [54, 55].
These data suggest that these proteins may serve as the
energy-transducing component of chromatin-remodeling
machines.
CBP·SRC-1·p/CAF: The complex with HAT activity.
A highly ordered chromatin structure presents a physical
obstacle for gene transcription, presumably by limiting
the access of transcription factors and RNA polymerase
II core machinery to the target DNA. Histone acetyla-
tion results in decreased affinity between core histone
subunits and DNA, and is correlated with transcriptional
activation, whereas the opposite is true of hypoacetylated
histones [56]. The rates of gene transcription roughly cor-
relate with the degree of histone acetylation [57]. Thus,
the specific recruitment of a complex with HAT activity
to a promoter may play a critical role in overcoming re-
pressive effects of chromatin structure on transcription
[57].
It has been demonstrated that CBP/p300 [58, 59] and
p/CAF contain HAT domains and have strong HAT ac-
tivities. The carboxyl terminus of NCoA1/SRC1/p160
[60] and pCIP/ACTR/AIB1 [26] have been reported
to possess HAT activity, though this activity is much
weaker than the HAT activity of CBP/p300, and p/CAF.
NCoA1/SRC1/p160 has been shown to interact with
a conserved region in the carboxyl terminus of CBP
and p300 and result in the cooperative formation of
CBP·SRC1·p/CAF complex which brings HAT activity
to nuclear receptor complex. Based on the presence of
three regulatory domains, members of the p160 family
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have been suggested to function as co-activators, at least
in part, by serving as adapter molecules that recruit CBP
and/or p300 complexes to promoter-bound nuclear re-
ceptors in a ligand-dependent manner [28, 61].
TRAP·DRIP·ARC: The complex for recruitment of
RNA polymerase. In addition to coactivator complexes
that harbor ATP-dependent nucleosome remodeling or
HAT activities, other coactivator complexes without in-
trinsic HAT activity have been identified. The best char-
acterized of these is the TRAP·DRIP·ARC complex that
enhances the transcriptional activities of nuclear recep-
tors. This complex is recruited to nuclear receptors in
a ligand-dependent manner via a 220 kD component
referred to as PBP/TRIP2/TRAP220/DRIP205, which
contains two alternatively utilized LXXLL nuclear recep-
tor interaction motifs [62]. The TRAP·DRIP·ARC com-
plex consists of more than a dozen polypeptides, a subset
of which appears to constitute modules that are compo-
nents of other activator complexes, including CRSP, Sup-
pressor of RNA polymerase B (SRB)/MED-containing
cofactor complex (SMCC) and mouse mediator [63, 64].
These factors have no known enzymatic functions and
may function to recruit RNA polymerase II holoenzyme
to ligand-bound nuclear receptors.
Corepressor complexes
NCoR and SMRT contain multi-independent repres-
sor domains that can interact with proteins that medi-
ate transcriptional repression, including Sin3 deacetylase
and histone deacetylase (HDACs). This interaction is dy-
namically regulated and exhibits promoter and cell-type
specificity [65, 66]. Corepressors can disrupt activating in-
teractions with the basal transcription apparatus, and/or
recruit enzymes with HDAC activity that provides a crit-
ical step in active repression [67].
NcoR·mSin3·HDAC. NcoR·mSin3·HDAC complex is
a basic repressor complex which has been proposed to
be recruited via the NCoR or SMRT and required for
repression mediated by unliganded nuclear receptors.
The core mSin3 complex contains multiple components
including retinoblastoma suppressor protein associated
protein 46, 48 (RbAp46,48), HDAC1,2 and two small
proteins, Sin-associated protein 30 and 18 (SAP30 and
SAP18) which could serve as an adapter to bridge the con-
nection between the core mSin3 complex and sequence-
specific transcriptional repressors [68, 69]. This complex
possesses HDAC activity and is thought to reverse actions
of HAT-containing complexes.
SMRT·HDAC3·TBL1. Another corepressor com-
plexes from HeLa cells termed SMRT·HDAC3·TBL1
complex has recently been identified, which poten-
tiates active repression [47]. These repression func-
tions may be augmented by additional interactions with
the NcoR·mSin3·HDAC complex, as well as HDAC4,
HDAC5, and HDAC7 [70, 71], implying a redundant or
combinatorial deacetylase-dependent repression [47].
Molecular switch for gene transcription: Coactivators
and corepressors in the integration of transcriptional
response
Coactivators and corepressors seem to counteract the
effects of one another in a “yin-yang” fashion, resulting
in a homeostatically regulated and balanced control of
transcription. Kinetically, transcription may be viewed as
a multistep procedure: a derepression process followed
by transcriptional initiation. The former refers to relief of
the repression imposed by high order chromatin structure
and the latter is assembly of the core RNA polymerase II
machinery and the initiation of transcription. It is likely
that different protein complexes can act either sequen-
tially, combinatorially, or in parallel to manipulate gene
transcription [36, 72]. Binding of hormone or ligand re-
sults in a conformational change in the ligand-binding do-
main that reduces affinity for NCoR or SMRT complexes
while simultaneously enhancing affinity for coactivators
that contain a conserved LXXLL interaction motif [3].
Initially, Brg-1·Brm-like complexes carry out chromatin
remodeling while ligand-dependent recruitment of p160
factors bring required HAT activities, in concert with
other factors such as CBP, p300, and p/CAF. Finally, re-
cruitment of complexes such as the TRAP·DRIP·ARC
complex may function to enhance RNA polymerase II
recruitment to the promoter, thereby converting the re-
ceptor from a transcriptional repressor to an activator
(Fig. 3).
MODIFICATIONS OF COREGULATOR ACTIVITY
The coregulator can be modified by acetylation,
methylation, proteolysis, and phosphorylation. These
modifications may change translocation or function of
coregulators and provide a combinatorial code for tissue-
and gene-specific gene transcription.
Acetylation and methylation
Many coregulators, including CBP, p300, pCAF, and
GCN5 have acetyltransferase activities which result in
histone acetylation and transcriptional activation after
being recruited by nuclear receptor in ligand-dependent
manner. In addition, acetylation of other coregulators is
a critical regulatory event for transcriptional regulation.
For example, the p160 coactivator, such as NCoA3/pCIP/
ACTR/AIB1/RAC3/TRAM1/SRC3/p160 can be acety-
lated by CBP in a ligand-dependent manner. This event
has a negative effect on the interaction of this coacti-
vator with nuclear receptors, thus providing a putative
negative feedback loop on ligand-induced transcrip-
tion [73]. Protein methylation may also affect gene
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transcription. It has been demonstrated that the nuclear
receptor coactivator CARM1 is an arginine methyltrans-
ferase that is complexed with other coactivators, such
as NCoA1/SRC1/p160 [18]. Additional protein methyl-
transferases, such as PRMT1, have recently been shown
to interact with p160s and increase nuclear receptor tran-
scriptional activity [19]. It has been shown that several
RNA processing factors can be modulated by methyla-
tion which may modulate gene transcription [74].
Proteolysis
Another mechanism for modulating cellular coregula-
tor levels is regulated proteolysis which links to cell cycle
regulation [75]. Several proteins involved in proteolysis
have been suggested as nuclear receptor coregulators, in-
cluding TRIPs [76]. Recent studies have demonstrated
that the corepressor NCoR, which binds to unliganded
nuclear receptors and antagonist-bound steroid recep-
tors, can be regulated proteolytically. Specifically, the
seven-in-absentia-homologue-2 (Siah2) binds to the N-
terminus of NCoR, and mediates proteasome-dependent
proteolysis which decreases NcoR protein levels [77].
This is a good example of how regulated proteolysis can
lead indirectly to an increase of transcriptional activity.
Phosphorylation
The functions of coactivator and corepressor com-
plexes can be regulated by multisignal transduction path-
ways. Phosphorylation events may result in increased
or decreased affinity between protein factors, leading to
changes in components of the complexes. One example is
the SWI-SNF complex, the components of which change
at different stages of the cell cycle. In addition, its chro-
matin remodeling activity depends on the phosphory-
lation state of some of the subunits, such as Brg1 [78].
CBP/p300 can be phosphorylated in vivo [79]. The HAT
activity of CBP/p300 can be regulated by signal-induced
phosphorylation events and also by cyclin-dependent ki-
nases, which presumably alter its coactivator activities
during the cell cycle [80]. Activation of different intra-
cellular signaling pathways and kinase cascades by mem-
brane receptors modulates coactivator complexes, and
seems to determine which acetyltransferases, such as CBP
or pCAF, are recruited to a particular coactivator com-
plex in a specific context [81]. In addition to CBP and
p300, a large number of coactivators, including the p160
factors, have recently been reported to be substrates for
different kinases. For example, the phosphorylation of
p160 coactivators in response to different signaling events
can cause redistribution of p/CIP from the cytoplasm to
the nucleus.
Similarly, corepressors are apparent targets of signal
transduction pathways. Activation of mitogen-activated
protein (MAP) kinase cascades correlates with a redis-
tribution of SMRT from a predominantly nuclear lo-
cation to a predominantly perinuclear or cytoplasmic
compartment [82]. It has been shown that the associ-
ation of NCoR and SMRT with nuclear receptors is
also modulated by cell signaling events. For example,
phosphorylation of the estrogen receptor N-terminus by
activation of MAP kinase decreased association of NCoR
with estrogen receptor occurs in the presence of the an-
tagonist tamoxifen [35]. The serine phosphorylation of
thyroid hormone receptor b1 inhibits interactions be-
tween SMRT and nuclear receptors [83]. It has been also
demonstrated that signal-dependent phosphorylation of
c-Jun results in removal of NCoR/HDAC3/TBL1/TBLR1
complexes through recruitment of a specific ubiquityla-
tion complex. This procedure allows binding of c-Jun/c-
Fos heterodimers and transcriptional activation of AP-1.
Therefore, phosporylation can contribute to increased
coactivator and decreased corepressor activity.
Translocation
Certain nuclear receptor coregulators with no known
DNA-binding capacity of their own might shuttle
between intracellular compartments, including TRIP4/
ASC1 [84] and NCoA3/pCIP/ACTR/AIB1/RAC3/
TRAM1/SRC3/p160 [33]. These coactivators are located
primarily in the cytoplasm of quiescent fibroblasts and
in the nucleus of mitotic cells, thereby establishing a
connection between subcellular localization and the
mitotic state of the cell. It has been demonstrated that
the translocation of coactivators is influenced by phos-
phorylation and CBP. For example, the translocation of
NCoA3/pCIP/ACTR/AIB1/RAC3/TRAM1/SRC3/p160
is enhanced by phosphorylation [33]. In addition, TRIP4/
ASC1/CG11710 translocates to the nucleus after co-
transfection with CBP in quiescent rat-1 cells, suggesting
acetyltransferase activity of CBP may be involved in the
mechanism [84].
NCoR is localized both in the nucleus and the cyto-
plasm suggesting that corepressors also can translocate
[85]. MAP kinase kinase (MEKK1 kinase) enhances the
nuclear location of SMRT. However, very little is under-
stood regarding the regulation of shuttling of coactivators
and corepressors.
NUCLEAR RECEPTORS/COREGULATORS IN
KIDNEY DISEASES
Since the progression of renal diseases is almost always
associated with inflammatory processes, metabolic disor-
ders, cell proliferation, hypertrophy and apoptosis, matrix
expansion, and hypertension, the importance of nuclear
receptors and their coregulators in these contexts will be
addressed.
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The role of nuclear receptors in regulation
of inflammation
Inflammatory mediators are pathogenic in many renal
diseases but inflammation affects renal function by dif-
ferent mechanisms. NF-jB is a cytokine-inducible tran-
scription factor that plays a key role in the expression
of a variety of genes involved in inflammatory responses
and cell survival. In acute inflammation, NF-jB is ac-
tivated and increases the expression of multiple proin-
flammatory genes. It has been demonstrated that NF-jB
acts as coregulator for nuclear receptor–mediated tran-
scriptional regulation and recruits a coactivator complex
that has striking similarities to that recruited by nuclear
receptors.
Like nuclear receptors-dependent gene expression,
NFjB-dependent gene expression requires specific
LXXLL motifs in one of the p160 family members.
It has been shown that a member of the p160 family,
NCoA1/SRC1/p160, potentiates the transcriptional ac-
tivity of NF-jB by interacting with the p50 component of
NF-jB [88]. Microinjection of anti-NCoA1/SRC1/p160
demonstrates that this coactivator is essential for p65-
dependent transactivation in vivo. The second member
of the p160 family NCoA2/TIF2/GRIP1/p160 also stim-
ulates NF-jB–dependent gene expression.
The CBP-associated protein p/CAF is another impor-
tant component of the NF-jB coactivator complex. The
enhancement of NF-jB activity requires the HAT activity
of p/CAF [61]. Microinjection of anti-p/CAF antibodies
into living cells blocked p65 transactivation. The p65 com-
ponent of NF-jB can also bind to the coactivator CBP
and p300 [89]. Although NF-jB does not require CBP’s
HAT activity [90], CBP provides a platform for a variety
of proteins that are important in NF-jB–dependent gene
expression.
NF-jB–dependent activation requires the p160 fam-
ily, CBP, and p/CAF. Interestingly, none of these coacti-
vators can function alone, which suggests that they may
form functional complexes in vivo. Additionally, overex-
pression of any of the coactivators leads to activation of
transcription, suggesting that their amounts are limited in
vivo [91]. These data suggest that nuclear receptor coreg-
ulators could be determinants for NF-jB activation and
could be useful targets in preventing NF-jB–mediated
inflammation in kidney disease.
On the other hand, although glucocorticoids, a lig-
and for glucocorticoid receptor, are the most power-
ful anti-inflammation drugs the detailed mechanisms of
glucocorticoid action in idiopathic nephrotic syndrome
and progressive glomerulonephritides have not been
clearly elucidated. It has been shown that all subsets
of human glomerular cells definitely express the glu-
cocorticoid receptor protein [92]. Glucocorticoid recep-
tor a inhibits the expression of the cytokines, including
interleukin (IL)-1b , tumor necrosis factor-a (TNF-a),
granulocyte monocyte-colony-stimulating factor (GM-
CSF), IL-4, IL-5, and IL-8. In addition, many other
nuclear receptorss, such as PPARs and retinoic acid re-
ceptors, have also been shown to have powerful anti-
inflammation features. Ligands of PPARs significantly
inhibit proinflammatory cytokines, such as vascular cell
adhesion molecule-1 (VCAM-1) and IL-6 expression in
various cell types [93, 94]. It has been demonstrated that
all three PPAR isoforms are differentially expressed in
the kidney [95]. Recently, we have demonstrated that
both eicosapentaenoic acid (EPA) and docosahexcenoic
acid (DHA) which are x-3 polyunsaturated fatty acids
and thought to be ligands for PPARs down-regulate
lipopolysaccharide (LPS)-induced activation of NF-jB
via a PPARc-dependent pathway in human kidney-2
(HK-2) cells [96].
PPARs and glucocorticoid receptor a inhibit the ex-
pression of proinflammatory genes by antagonizing the
effects of other classes of transcription factors such as NF-
jB, AP-1, and STAT [97, 98]. Their anti-inflammatory ac-
tions can be exerted through different mechanisms. First,
they can alter signaling pathways leading to transcription
factor activation. For example, glucocorticoid receptor a
can inhibit Jun kinase activity leading to the abolition of
c-Jun phosphorylation and subsequent AP-1 activation.
PPARs repress NF-jB transcriptional activity in a ligand-
dependent manner by either inhibiting IjB kinase and
consequently preventing IjB degradation, or increasing
IjB expression in cytokine-stimulated mesangial cells
[99]. The inhibitory effect of glucocorticoid receptor a
and PPARs on AP-1, NF-jB, and STAT-dependent genes
might also be due to competition for the recruitment of
their coactivator CBP/p300, the concentration of which
is functionally limiting, and which is a common coactiva-
tor of these transcription factors. Thus activation of one
factor could result in an inhibitory effect in others be-
cause of limited CBP/p300 [100]. Glucocorticoid recep-
tor a and PPARs can also inhibit gene transcription by
directly interacting with AP-1, NF-jB, and STAT [101].
An additional mechanism whereby glucocorticoid recep-
tor and PPARs can alter gene expression is by modify-
ing the acetylation of histones. Glucocorticoids repress
histone acetylation by directly inhibiting CBP-associated
HAT activity and by recruiting histone deacetylases [102].
As noted above, the deacetylation of histones reduces ac-
cess of the transcription factors, such as AP-1 and NF-jB,
to their response elements on DNA. Finally, PPARs and
glucocorticoid receptor a can bind NCoR, a corepressor
molecule, to exert anti-inflammatory activity.
Lipid-mediated renal and vascular injury: Role of nuclear
receptor and its coregulators in cholesterol homeostasis
Cardiovascular disease is the most important cause of
death at all stages of progression of renal disease, ac-
counting for approximately 50% of the mortality among
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patients on long-term dialysis and after renal transplan-
tation [103]. In addition, lipid-mediated injury plays an
important role in the pathogenesis of many renal dis-
eases, including diabetic nephropathy [104, 105]. Dia-
betic kidneys specifically express several genes normally
found in adipocytes, including adipocyte differentiation-
regulated protein (ADRP) or adipophilin in humans,
suggesting a switch of kidney phenotype in favor of
lipid accumulation in diabetes. Many nuclear receptors
(termed as metabolic nuclear receptors) and their coreg-
ulators play an important role in controlling cellular and
whole-body sterol homeostasis, including (1) fatty acid,
triglyceride, and lipoprotein metabolism via PPARa, b/d,
and c, (2) reverse cholesterol transport and cholesterol
absorption through the liver X receptors and liver recep-
tor homologue-1 (LRH-1), and (3) bile acid metabolism
through the farnesol X receptor, liver X receptors, and
LRH-1 [107].
PPARs are important in controlling the homeostasis
of fatty acid and triglyceride, which are increased in the
patients with chronic renal failure. Binding to PPARa by
fatty acid, eicosanoid, and fibrate drug ligands leads to
activation of numerous genes involved in the uptake and
b oxidative catabolism of fatty acids in heart, kidney, and
muscle. Increased diversion of fatty acids into b oxida-
tion decreases the availability of fatty-acyl conenzymeA
(CoA) substrates for triglyceride synthesis and, there-
fore, decreases VLDL secretion by the liver [108]. PPAR
agonists may also decrease triglyceride levels by increas-
ing the expression of lipoprotein lipase (LPL) in the liver
(PPARa) and in adipocytes, skeletal muscle (PPARc),
and macrophages (PPARa and c) [109, 110].
Liver X receptors regulate the expression of genes
involved in cholesterol and fatty acid homeostasis,
including the genes for ABCA1 and SREBP1. Liver X
receptors are thought to be a cholesterol sensor in periph-
eral tissue, including kidney, blood vessel, and monocyte-
macrophages. We and others have previously shown that
liver X receptor a is expressed in renal glomeruli and
functionally present in mesangial cells where its activa-
tion mediates cholesterol efflux via ABCA1 [111, 112].
Liver X receptors are regulated by oxidized derivatives
of cholesterol termed oxysterols and heterodimerize with
retinoid X receptors [113]. Direct regulation of liver X
receptor by oxysterols, liver X receptor autoregulation,
indirect regulation of liver X receptor via PPARa and
PPARc, and possibly liver X receptor–independent regu-
lation by PPARb/d induces ABCA1 expression in periph-
eral tissue [1]. ABCA1 transporter pumps cholesterol
out of cells and processes it into high-density lipoprotein
(HDL), which the liver removes from the blood stream.
Defective ABCA1 in patients with Tangier disease results
in very low HDL and cholesterol-stuffed macrophages
that form foam cells, which can cause atherogenesis.
Although activation of liver X receptor leads to ABCA1-
mediated cholesterol efflux from kidney cells, the possi-
ble adverse effect is that an enhanced SREBP1c induced
by liver X receptor may increase fatty acids synthesis
and plasma triglyceride levels. It has been demonstrated
that unliganded liver X receptor inhibits its target gene
ABCA1 expression and that loss of liver X receptor in
liver X receptor−/− mice leads to derepression of the
ABCA1 gene in macrophages and the intestine, while
the SREBP1c gene remains transcriptionally silent [10].
It is important to develop synthetic ligands for liver X
receptors which remove active suppression induced by
unliganded liver X receptor, without activating its target
gene SREBP1c.
In liver, farnesoid X receptor which senses bile acids
also dimerizes with retinoid X receptor. When activated,
it shuts off bile production by stimulating transcription of
the small heterodimer partner (SHP), which is an orphan
receptor and strong inhibitor of CYP7A1, a target gene
of liver X receptor-retinoid X receptor [1]. The inhibition
of CY7A1, the rate-limiting enzyme in bile acid produc-
tion, lowers bile availability in the intestine, hindering the
emulsification and absorption of cholesterol and other
fats. Therefore, liver X receptor and farnesoid X recep-
tor act as sensors in different tissues to keep cholesterol
absorption and transport in balance.
We have previously demonstrated that inflamma-
tion can disrupt this fine balance and promote intra-
cellular lipid accumulation in human mesangial cells
(HMCs) by inhibiting cholesterol efflux through inhi-
bition of the PPAR-liver X receptor-ABCA1 pathway
[111], presumably, it also increases bile acid synthesis
and cholesterol absorption which may contribute dyslipi-
demia in the patients with chronic renal diseases. Both
PPARa and PPARc ligands prevent lipid accumulation in
HMCs [111]. These results suggest potential mechanisms
whereby inflammation may exacerbate lipid-mediated
cellular injury in the glomerulus and in other tissues, and
indicate that PPAR agonists may have a protective effect.
Glucose-mediated renal and vascular injury:
Role of nuclear receptor and its coregulators
in glucose homeostasis
Microvascular injury and mesangial dysfunction con-
tribute to the pathogenesis of diabetic glomerulosclero-
sis. All three PPAR isoforms seem to play important roles
in the development of diabetic nephropathy in type 2 di-
abetes. PPARc mRNA is reduced by 77% in glomeruli
of diabetic mice [114]. PPARc agonists, such as thiazo-
lidinediones, have been used as insulin-sensitizing agents
for treating diabetes and metabolic syndrome [115] and
also provides superior renal protection in a rat model of
type 2 diabetes with obesity by reducing the proteinuria
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and glomerular and tubular kidney damage [116]. On the
other hand, both mRNA and protein of PPARa are el-
evated in glomeruli, cortical tubules, and renal arterial
vessels of db/db mice [106]. Interestingly, there is some ev-
idence to suggest either activating or inhibiting a nuclear
receptor may have a similar biologic effect. For example,
both PPARc agonist and antagonist improve insulin resis-
tance in type 2 diabetic subjects and have clinical poten-
tial for the treatment of diabetes type 2 and obesity [117].
Glucose metabolism is tightly controlled by a variety of
hormones, including insulin, epinephrine, glucagon, and
glucocorticoids acting on various cell types, including kid-
ney. It has been demonstrated that dexamethasone induc-
tion of hypertension and diabetes is PPARa-dependent
in LDL receptor-null mice, suggesting that activation of
PPARa may involve in glucocorticoid-induced insulin re-
sistance and hypertension [119].
HNF4a protein, an orphan receptor, was detected
in glomerulus, and distal and collecting tubular epithe-
lial cells of kidney. A loss-of-function mutation in hu-
man HNF4a causes a form of diabetes mellitus called
maturity-onset diabetes of the young type 1 (MODY1)
which is characterized in part by a diminished insulin se-
cretory response to glucose [120]. Vitamin D receptor is
decreased in both intestine and kidney of genetically dia-
betic db/db mice which may link to hyperplasia of kidney
[121].
Cell proliferation, differentiation, and apoptosis
It has been shown that many nuclear receptors and
their coregulators are involved in the regulation of cell
proliferation, differentiation, and apoptosis. Cytokine-
driven proliferation plays important roles in the develop-
ment of glomerulosclerosis. All three isoforms of PPARs
have been suggested to play a role in regulating the cell
cycle and in carcinogenesis. It has also demonstrated
that PPARc ligands rosiglitazone and troglitazone inhibit
platelet-derived growth factor–induced DNA synthesis
in rat mesangial cells [122]. PPARc activation may in-
hibit mesangial growth directly by affecting MAP kinase
and cell cycle regulatory proteins [123]. PPARc activa-
tion also significant inhibits HK-2 proliferation induced
by high glucose. In vivo, PPARc agonist troglitazone pro-
tects against nondiabetic glomerulosclerosis in rats inde-
pendent of insulin/glucose effects and is thought to be
associated with regulation of glomerular cell prolifera-
tion and hypertrophy [125].
Another nuclear receptor involving in mesangial
cell proliferation is vitamin D receptor [126]. 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) has a major in-
hibitory effect on the G1/S checkpoint of the cell cycle
by up-regulating the cyclin-dependent kinase inhibitors
p27 and p21, and by inhibiting cyclin D1 [127]. We have
demonstrated that 1,25(OH)2D3 inhibits mesangial cell
proliferation via vitamin D receptor (Ruan, unpublished
data). Vitamin D receptor function is impaired by several
factors including hypocalcemia, hyperphosphatemia, ac-
cumulation of uremic toxins, and reduction in cellular
levels of the vitamin D receptor partner, retinoid X re-
ceptor [128], which may result in mesangial cell prolif-
eration. In addition, retinoids play a fundamental role
in regulating normal cell proliferation and differentia-
tion in either a retinoic acid receptor–dependent or in-
dependent manner [129]. Retinoids also limit glomerular
proliferation, glomerular lesions, and albuminuria in an
established model of renal damage.
Activation of retinoic acid receptors by ligands pre-
vents puromycin aminonucleoside nephrosis (PAN) and
oxidative stress–induced apoptosis in podocytes and
mesangial cells [131]. On the other hand, 1,25(OH)2D3
via vitamin D receptor may induce apoptosis either indi-
rectly through effects on the insulin-like growth receptor
and TNF-a or more directly via the Bcl-2 family system,
the ceramide pathway, the death receptors (e.g., Fas) and
the stress-activated protein kinase pathways (Jun N ter-
minal kinase and p38) [127]. In addition, nerve growth
factor (NGF)-induced factor B (NGFIB) is an inducible
orphan nuclear receptor that initiates apoptosis [132].
p300 seems also to be involved in apoptosis control in
mesangial cells [133].
Matrix expansion and renal fibrosis
Diabetic glomerulosclerosis is characterized by the ac-
cumulation of extracellular matrix in the mesangium.
Estrogens seem to retard whereas estrogen deficiency
seems to accelerate progressive glomerulosclerosis. Es-
trogen action is mediated via estrogen receptor sub-
types a and b . Both estrogen receptor subtypes were
expressed in human and mouse mesangial cells. It has
been demonstrated that estrogens suppress transform-
ing growth factor-b (TGF-b)–induced gene expression,
such as type IV collagen in kidney mesangial cells. Es-
trogen also increased matrix metalloproteinase 9 (MMP-
9) activity which results in extracellular matrix turnover
and protects against progression of diabetic glomeru-
losclerosis [135]. Estrogen receptor modulator LY-117018
suppressed mesangial cell type IV and type I collagen
gene expression in a dose-dependent manner. Genistein,
which selectively binds to estrogen receptor b suppressed
type I and type IV collagen synthesis, suggesting that es-
trogen receptor b mediates the effects of estrogen on
collagen synthesis. In addition, estrogens also exert po-
tent antioxidant effects that may contribute to the pro-
tective effect of female gender on the course of renal dis-
ease [137]. These observations suggest that sex hormones
per se may be important determinants of the greater
susceptibility of the male kidney to progressive renal
injury.
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It has been shown that PPARa ligands inhibit H2O2-
mediated activation of TGF-b1 in HMCs. Troglitazone, a
PPARc agonist, suppresses the secretion of type I colla-
gen by mesangial cells in vitro and also prevents mesan-
gial expansion and glomerulosclerosis in diabetic rats
[139]. Pioglitazone inhibits TGF-b–induced fibronectin
expression by inhibiting AP-1 activation dependent on
PPARb , while 15d-prostaglandin J2 (PGJ2) acts through
a dual mechanism independent of and dependent on
PPARc activation in mouse mesangial cells [140].
It has been reported that coactivator SRC-1 mRNA
level is down-regulated by dexamethasone treatment in
rat renal mesangial cells in vitro, and p300 is important
molecule in TGF-b/Smad-pathway-mediated a2(I) col-
lagen expression in mouse mesangial cells [141].
Hypertension
High blood pressure is a common finding in severe
nephritic patients. The renin-angiotensin-aldosterone
system (RAAS) plays an important role in its patho-
genesis. Aldosterone acting through Mineralocorticoid
receptor is thought to play a role in the development
of hypertension. Aldosterone receptor antagonists have
been shown to antagonize all these effects in experi-
mental models [142]. Glucocorticoid receptor activation
by glucocorticoids enhances blood pressure by inducing
water retention and increasing plasma angiotensinogen
concentration through increased hepatic synthesis [143].
On the other hand, activation of retinoic acid receptor
by retinoids can intervene in the above systems and re-
duce systemic blood pressure and RAS activity [144].
The antihypertensive effect of the PPARc agonist rosigli-
tazone has been reported in patients with diabetes or
obesity [145]. Cytochrome P450–dependent arachidonic
acid metabolites may act as mediators in the regulation
of vascular tone and renal function. It has been shown
that both PPARa and cytochrome P4504A are expressed
in renal proximal tubules. Treatment with clofibrate, the
PPARa agonist, increased cytochrome P4504A protein
levels and production of 20-hydroxyarachidonic acid (20-
HETE) which may ameliorate hypertension by restoring
P450-dependent arachidonic acid hydroxylase activities
[147]. Recently, liver X receptor has been identified as
cAMP-responsive nuclear modulator of renin and c-myc
expression; liver X receptor a activated renin gene ex-
pression may play an important role in blood pressure
control [148].
Others
Nuclear receptors also play very important role in re-
nal development, calcium/phosphorus metabolism, and
elimination of harmful endogenous and exogenous
c¨¨ompounds. For example, Deficiency of retinoic acid
receptor causes abnormalities in fetal kidneys and re-
duced nephron number, which might be responsible for
adult diseases such as hypertension and nephritis [149].
Vitamin D receptor forms vitamin D receptor · retinoid
X receptor·coregulator complex which binds to vitamin
D response elements in the promoter region of target
genes to regulate the homeostasis of calcium and phos-
phorus, and also controls the expression of parathy-
roid hormone (PTH). It has been shown that impaired
production of 1,25(OH)2D3 and reduced parathyroid
vitamin D receptor content in chronic kidney disease
are major contributors to the generation and mainte-
nance of parathyroid hyperplasia and increased syn-
thesis/secretion of PTH [128]. There are many patients
(>40% in some series) with chronic renal failure in whom
administration of 1,25(OH)2D3 does not decrease serum
PTH levels [150]. This may be related to a number of
factors, such as decreased parathyroid levels of the vita-
min D receptor and the calcium-sensing receptor, mono-
clonality of the parathyroid hyperplasia, and hyperphos-
phatemia [151]. In addition, increased calreticulin in-
duced by hypocalcemia prevents the binding of vitamin
D receptor · retinoid X receptor to vitamin D response
response element and results in the transcriptional ef-
fect of 1,25(OH)2D3 on the PTH gene [151]. Detoxifica-
tion is mainly through hepatic cytochrome P450 enzymes
which are pregsnane X receptor target gene, and both
pregsnane X receptor and cytochrome P4503A express
in kidney, one of the sites of drug-metabolism [152]. Dys-
regulation of pregsnane X receptor may be involved in
drug, or endo-, and xenobiotic-mediated renal injury.
CONCLUSION
Nuclear receptors can serve as activators or repres-
sors dependent on the exchange or binding of coregula-
tor complexes. These processes are regulated by various
signal transduction pathways. The role of coregulators
in controlling gene transcription in kidney cells remains
less explored and further investigation will be required.
It is clear that many nuclear receptors and coregula-
tors are key factors in regulating inflammatory processes,
metabolic disorders, cell proliferation, apoptosis, hyper-
trophy, and hypertension. These nuclear receptors and
their coregulators may be useful targets for medication.
It is possible to develop ligands with a large spectrum
of full, partial, or inverse agonist or antagonist activity
as well as compounds called selective nuclear receptor
modulators that activate only a subset of the function in-
duced by cognate ligand or that act in a cell type–selective
manner. Such studies will lead to novel prevention and
treatment strategies for many chronic renal diseases and
its complications, such as atherosclerosis. The analysis
of nuclear receptor functions in health and disease, as
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reviewed, underscores a critical role for these recep-
tors and their cognate ligands in the fine-tuned adaptive
responses to fluctuating metabolic demands and inflam-
matory stresses.
ABBREVIATIONS
ABCA1 ATP binding cassette A1
ACTR Activator of the thyroid and RA receptor
AIB1 Amplified in breast cancer 1
ARA Androgen receptor activator
ARC Activator-recruited cofactor
ARIP Androgen receptor-interacting protein
ASC Activating signal co-integrator
BRG Brahma-related gene
CARM Coactivator-associated arginine methyltransferase
CBP CREB-binding protein
CREB cAMP-response element-binding protein
CRSP Coactivator required for Sp1 activation
DAX1 DSS-AHC critical region on the chromosome gene 1
DRIP Vitamin D receptor-interacting protein
ETO Eight-twenty-one translocation
GCN General control of amino acid synthesis
GBP RNA helicase Gu binding protein
GCNF Germ cell nuclear factor
GRIP Glucocorticoid receptor interacting protein
HAT Histone acetyltransferase
HDAC Histone deacetylase
MAP Mitogen-activated protein
MEKK MAP kinase kinase kinase
NCoA Nuclear receptor coactivator
NCoR Nuclear receptor corepressor
NF-jB Nuclear factor-jB
NGFIB NGF-induced factor B
NRC Nuclear receptor coregulator
pCAF p300/CBP-associated factor
pCIP p300/CBP cointegrator-associated protein
PBP PPAR binding protein
PIAS Protein inhibitor of activated STAT
PGC PPAR c coactivator
PKA cAMP-dependent protein kinase
PRIP PPAR-interacting protein
PRMT Protein arginine methyltransferase
RAC Receptor-associated coactivator
RAP Nuclear receptor-activating protein
RB Retinoblastoma suppressor protein
RIP Receptor-interacting protein
SAP mSin3 associated protein
SMAD Similar to mad
SMCC SRB/MED-containing cofactor complex
SMRT Silencing mediator of retinoic acid and thyroid hormone
receptor
SNF Sucrose nonfermenting
SRA Steroid receptor RNA activator
SRB Suppressor of RNA polymerase B
SRC Steroid receptor coactivator
SREBP Sterol-responsive element-binding protein
STAT Signal transducer and activator of transcription
SWI Switch
TAF TBP-associated factor
TBP TATA-binding protein
TBL Transducin-like protein 1
TBLR TBL1-related protein
TIF Transcriptional intermediary factor
TRAC Thyroid hormone receptor associated cofactor
TRAM Thyroid hormone receptor activator molecule
TRAP Thyroid hormone receptor associated protein
TRBP Thyroid hormone receptor binding protein
TRIP Thyroid hormone receptor interacting protein
UCP-1 Uncoupling protein 1
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